Richard Thomas Layer
Pharmacy in Salt Lake City, UT

6399574, Jun 4, 2002

Mar 22, 2000

09/533889

R. Tyler McCabe - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Richard T. Layer - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT

University of Utah Research Foundation - Salt lake City UT
Cognetix, Inc. - Salt lake City UT

A61K 3800

514 12, 514 2, 514 13, 530300, 530326, 530324, 530325, 4241851

The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more -carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include, epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimers disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinsons disease, Huntingtons disease, Downs Syndrome, Korsakoffs disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-complusive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.

6515103, Feb 4, 2003

May 11, 2000

09/142080

Fe C. Abogadie - London, GB
Lourdes J. Cruz - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
Craig Walker - Salt Lake City UT
Clark Colledge - Alpine UT
David R. Hillyard - Salt Lake City UT
Elsie Jimenez - Qyezan, PH
Richard T. Layer - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Gregory S. Shen - Salt Lake City UT
R. Tyler McCabe - Salt Lake City UT
Jean E. Rivier - La Jolla CA

University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Salk Institute - LaJolla CA

A61K 3800

530326, 530300, 530327, 514 13, 514 14, 514 15, 514 21

The present invention is directed to conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more -carboxyglutamic acid residues. The conantokins are useful for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.

6172041, Jan 9, 2001

Feb 10, 1999

9/142078

R. Tyler McCabe - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Richard T. Layer - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT

University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT

A61K 3800, C07K 500, C07K 700

514 12

The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more. gamma. -carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-compulsive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.